Outlook Therapeutics, Inc. Stock News

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known ...

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

Access the segment  here

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure

Video webcast now available  here

The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accomp...